T-E. Ciuleanu - Concepedia

Author

T-E. Ciuleanu

Institute of Oncology Prof. Dr. Ion Chiricuta

Also Known As

T Ciuleanu, T-E. Ciuleanu, T. Ciuleanu, T.-E. Ciuleanu, T.E. Ciuleanu, TE Ciuleanu

Publications

509

Citations

H-Index

Concepts

All Affiliations

Institute of Oncology Prof. Dr. Ion Chiricuta Bristol-Myers Squibb (United States)Hospital Universitario 12 De Octubre Vall d'Hebron Hospital Universitari Emory University

About

T-E. Ciuleanu is an author at Institute of Oncology Prof. Dr. Ion Chiricuta specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	301
2	Pathology	4	4	136
3	Health Sciences	3	3	88
4	Immunology	3	3	53
5	Pharmacology	3	3	66

T-E. Ciuleanu

Publications

380

Citations

H-Index

Page 1

	Year	Citations
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC) Chandra P. Belani, T. Brodowicz, T-E. Ciuleanu, Journal of Clinical Oncology Surgical OncologyAdvanced Lung DiseaseMaintenance PemetrexedMedicineCancer Management	2009	82
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial Hossein Borghaei, Kenneth J. O’Byrne, Luis Paz‐Ares, ESMO Open	2023	41
Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status Sanjay Popat, Andrea Ardizzoni, T-E. Ciuleanu, Annals of Oncology European Single-armPreclinical TherapeuticsUrologyMedicineCancer Management	2017	40
Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC). Carsten Reinhardt, Romuald Zdrojowy, Cezary Szczylik, Journal of Clinical Oncology ImmunodeficienciesImmunologyImmunoeditingImmunodominanceAntigen Processing	2010	27
4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status Suresh S. Ramalingam, David Balli, T-E. Ciuleanu, Annals of Oncology Advanced NsclcPart 1MedicinePharmacologyImmune Checkpoint Inhibitor	2021	25
PL-3 Results of the randomized international adjuvant lung cancer trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (PTS) with resected non-small cell lung cancer (NSCLC) Thierry Le Chevalier, Jean‐Pierre Pignon, Bengt Bergman, Lung Cancer Cisplatin-based ChemotherapyMedicinePl-3 ResultsMetronomic TherapyClinical Trials	2003	24
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Giorgio V. Scagliotti, Ihor Vynnychenko, Y. Ichinose, Journal of Clinical Oncology PathologyPharmacotherapyMetronomic ChemotherapyMetronomic TherapyClinical Trials	2011	24
O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC M. O’Brien, T-E. Ciuleanu, H. Tsekov, Lung Cancer Resistant SclcMedicineO-157 Survival BenefitPharmacotherapyCancer Treatment	2005	20
Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817 Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip, Annals of Oncology Advanced NsclcOncologyCheckmate 817Low-dose IpilimumabPharmacology	2019	17
Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial Andrea Camerini, Alessandro Morabito, Agnese Montanino, ESMO Open	2021	17

Page 1